Putney’s $6.7M In Series B Funding To Double Research And Development

Putney Inc, receives $6.7 million in Series B funding.

Putney Inc., a pharmaceutical company in Portland, Maine, focusing on generic drugs for companion animals, recently received $6.7 million in Series B funding.

The money will provide capital for the company to double the number of products under development for dogs and cats, double revenue and double the size of its management team, including 10 new hires in sales, marketing, business development and research and development.

The Series B funding round was led by investor Peter Werth and other financial investors such as a Pritzker family trust. Series A investors were also participants.

“We found Putney’s strategy and business plan to develop generic drugs for pets a compelling investment opportunity,” Werth said, chairman and president of Chemwerth Inc. “Putney’s excellent growth prospects are evidenced by its established customer alliances and nationwide reach in the veterinary channel.”

William Blair & Company, a global investment firm, acted as advisor to Putney on the Series B capital raise.


Leave a Comment



Sign-up for your account with Veterinary Practice News Canada. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News Canada.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, digital editions of the magazine, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.